SEC Company Response from Nuo Therapeutics, Inc. (AURX) (CIK 0001091596) (AURX) — Jul 1, 2013

Nuo Therapeutics, Inc. (AURX) (CIK 0001091596)
Date: July 1, 2013 · CIK: 0001091596 · Accession: 0001144204-13-037556

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-183703

Date

July 1, 2013

Author

Branch Chief

Form

CORRESP

Company

Nuo Therapeutics, Inc. (AURX) (CIK 0001091596)

Letter

Division of Corporation Finance United States Securities and Exchange Commission Re: Cytomedix, Inc. Post-effective amendment to Form S-3 on Form S-1 Filed July 1, 2013 File No. 333-183703

Dear Mr. Mancuso:

In connection with the above referenced filing, the Company acknowledges the following:

· should the Commission or the staff, acting pursuant to delegated authority declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filling effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing, and

· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very truly yours,
Cytomedix, Inc.

Show Raw Text

CORRESP
1
filename1.htm

Cytomedix, Inc.

209 Perry Parkway, Suite 7, Gaithersburg,
MD 20877

July 1, 2013

Mr. Russell Mancuso

Branch Chief

Division of Corporation Finance

United States Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549

 Re: Cytomedix, Inc.

Post-effective amendment to
Form S-3 on Form S-1

Filed July 1, 2013

File No. 333-183703

Dear Mr. Mancuso:

In connection with
the above referenced filing, the Company acknowledges the following:

 · should the Commission or the staff, acting pursuant to delegated authority declare the filing effective,
it does not foreclose the Commission from taking any action with respect to the filing;

 · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring
the filling effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure
in the filing, and

 · the Company may not assert staff comments and the declaration of effectiveness as a defense in
any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

    Very truly yours,

    Cytomedix, Inc.

    By:
    /s/ Steven A. Shallcross

    Name: Steven A. Shallcross

    Title:	  Executive VP, CFO

SecProbe.io